Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label studyThe authors report that none of them has a significant financial interest in any commercial goods/organization that may have a direct interest in manuscript. This research is not funded by any pharmaceutical company.
Saved in:
| Title: | Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study |
|---|---|
| Authors: | Akkaya, Cengiz, Sivrioglu, Enver Yusuf, Akgoz, Semra, Eker, Salih Saygin, Kirli, Selcuk |
| Source: | Human Psychopharmacology: Clinical & Experimental. Jul2006, Vol. 21 Issue 5, p337-345. 9p. 4 Charts, 4 Graphs. |
| Subjects: | Venlafaxine, Mental depression, Anxiety, Clinical trials, Psychopharmacology |
| Abstract: | Objective The aim of this study was to compare the efficacy and tolerability of reboxetine in the treatment of major depressive disorder (MDD) and MDD with anxiety features to venlafaxine XR. Method Patients with MDD, aging 18 between 65 years, were randomly allocated to two groups receiving either open-label venlafaxine XR capsules (n = 50) or reboxetine tablets (n = 43). Subjects were administered Hamilton Depression Rating Scale (HAM-D) and Hamilton Anxiety Scale (HAM-A) at baseline and 2, 4, 7, 10 weeks after the baseline visit. Results Response rates to antidepressant treatment were significantly higher in the venlafaxine XR group at 10th week. When patients having anxious depression were analysed separately; response rate for anxiety of reboxetine group was significantly higher at 7th week only. Mean number of side effects were significantly higher in reboxetine group. Only one subject in each group was dropped out due to side effect. Conclusion We may suggest that reboxetine is as effective and tolerable as venlafaxine XR in the treatment of MDD and MDD with anxiety features, and it may be considered a treatment option to venlafaxine XR. Copyright © 2006 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR] |
| Copyright of Human Psychopharmacology: Clinical & Experimental is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 21714329 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study<FNR></FNR><FN>The authors report that none of them has a significant financial interest in any commercial goods/organization that may have a direct interest in manuscript. This research is not funded by any pharmaceutical company. </FN> – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Akkaya%2C+Cengiz%22">Akkaya, Cengiz</searchLink><br /><searchLink fieldCode="AR" term="%22Sivrioglu%2C+Enver+Yusuf%22">Sivrioglu, Enver Yusuf</searchLink><br /><searchLink fieldCode="AR" term="%22Akgoz%2C+Semra%22">Akgoz, Semra</searchLink><br /><searchLink fieldCode="AR" term="%22Eker%2C+Salih+Saygin%22">Eker, Salih Saygin</searchLink><br /><searchLink fieldCode="AR" term="%22Kirli%2C+Selcuk%22">Kirli, Selcuk</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Human+Psychopharmacology%3A+Clinical+%26+Experimental%22">Human Psychopharmacology: Clinical & Experimental</searchLink>. Jul2006, Vol. 21 Issue 5, p337-345. 9p. 4 Charts, 4 Graphs. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Venlafaxine%22">Venlafaxine</searchLink><br /><searchLink fieldCode="DE" term="%22Mental+depression%22">Mental depression</searchLink><br /><searchLink fieldCode="DE" term="%22Anxiety%22">Anxiety</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+trials%22">Clinical trials</searchLink><br /><searchLink fieldCode="DE" term="%22Psychopharmacology%22">Psychopharmacology</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Objective The aim of this study was to compare the efficacy and tolerability of reboxetine in the treatment of major depressive disorder (MDD) and MDD with anxiety features to venlafaxine XR. Method Patients with MDD, aging 18 between 65 years, were randomly allocated to two groups receiving either open-label venlafaxine XR capsules (n = 50) or reboxetine tablets (n = 43). Subjects were administered Hamilton Depression Rating Scale (HAM-D) and Hamilton Anxiety Scale (HAM-A) at baseline and 2, 4, 7, 10 weeks after the baseline visit. Results Response rates to antidepressant treatment were significantly higher in the venlafaxine XR group at 10th week. When patients having anxious depression were analysed separately; response rate for anxiety of reboxetine group was significantly higher at 7th week only. Mean number of side effects were significantly higher in reboxetine group. Only one subject in each group was dropped out due to side effect. Conclusion We may suggest that reboxetine is as effective and tolerable as venlafaxine XR in the treatment of MDD and MDD with anxiety features, and it may be considered a treatment option to venlafaxine XR. Copyright © 2006 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Human Psychopharmacology: Clinical & Experimental is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=21714329 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1002/hup.770 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 9 StartPage: 337 Subjects: – SubjectFull: Venlafaxine Type: general – SubjectFull: Mental depression Type: general – SubjectFull: Anxiety Type: general – SubjectFull: Clinical trials Type: general – SubjectFull: Psychopharmacology Type: general Titles: – TitleFull: Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study<FNR></FNR><FN>The authors report that none of them has a significant financial interest in any commercial goods/organization that may have a direct interest in manuscript. This research is not funded by any pharmaceutical company. </FN> Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Akkaya, Cengiz – PersonEntity: Name: NameFull: Sivrioglu, Enver Yusuf – PersonEntity: Name: NameFull: Akgoz, Semra – PersonEntity: Name: NameFull: Eker, Salih Saygin – PersonEntity: Name: NameFull: Kirli, Selcuk IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 07 Text: Jul2006 Type: published Y: 2006 Identifiers: – Type: issn-print Value: 08856222 Numbering: – Type: volume Value: 21 – Type: issue Value: 5 Titles: – TitleFull: Human Psychopharmacology: Clinical & Experimental Type: main |
| ResultId | 1 |
